Education
About Us
Working with TipRanks
Follow Us
Galapagos (GB:0JXZ)
LSE:0JXZ
0JXZ Stock Chart & Stats
€28.40
€0.10(0.38%)
At close: 4:00 PM EST
€28.40
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€19.99 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.87B
Enterprise Value€1.80B
Total Cash (Recent Filing)€3.00B
Total Debt (Recent Filing)€12.10M
Price to Earnings (P/E)5.8
Beta0.80
Next Earnings
May 06, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.88
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.75Price Target Upside-19.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-1.91
Revenue Forecast (FY)€261.76M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and multi‑billion equity provide durable financial flexibility to fund R&D, pursue partnerships or absorb cash burn for multiple quarters without immediate refinancing. This structural strength supports strategic optionality and resilience through biotech development cycles.
Revenue & Profitability ReboundA sharp revenue and EBIT rebound in 2025 signals successful commercialization or milestone recognition and demonstrates the company can generate meaningful operating profits when key programs monetize. This shift supports reinvestment capacity and validates the business model beyond pre-commercial stages.
Partnership & Program OptionalityGilead's temporary waiver is a structural positive: it increases Galapagos' ability to seek external partners for a Phase 3‑enabling asset, expanding commercialization routes and negotiation leverage. That durable increase in deal optionality can accelerate program advancement and diversify future revenue sources.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow creates ongoing reliance on cash reserves or external financing despite a strong balance sheet. Over 2–6 months this elevates refinancing and dilution risk and constrains freedom to expand programs without clear near‑term cash generation improvements.
Exit Of Cell Therapy BusinessWinding down cell therapy removes a potentially high‑value, differentiated franchise and reduces pipeline diversification. Even with strong Phase 2 CAR‑T efficacy, exiting this area lowers long‑term growth optionality and forfeits future upside from proprietary cell therapy innovations.
Volatile Historical EarningsAn uneven earnings history with prior multi-year losses indicates underlying revenue and margin volatility. This limits predictability of future cash generation and increases execution risk for sustained profitability, making long‑term planning and partner negotiations more complex.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €19.99 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.87B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 66 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported €11.885 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €11.995.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.98.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €11.885 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 5.934%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€22.75
▼(-19.89% Downside)
Technical Analysis
Options Prices
Currently, No data available
---